A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001
Open Access
- 3 May 2020
- journal article
- case report
- Published by Elsevier BV in JACC: Case Reports
- Vol. 2 (9), 1331-1336
- https://doi.org/10.1016/j.jaccas.2020.04.025
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences of the United States of America, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- COVID-19: what has been learned and to be learned about the novel coronavirus diseaseInternational Journal of Biological Sciences, 2020
- Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment OptionsFrontiers in Cardiovascular Medicine, 2019
- Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2015
- Inhibition of Aldose Reductase Prevents Experimental Allergic Airway Inflammation in MicePLOS ONE, 2009
- Endotoxin-Induced Cardiomyopathy and Systemic Inflammation in Mice Is Prevented by Aldose Reductase InhibitionJournal of the American College of Cardiology, 2006